Doxycycline has been demonstrated to reduced left ventricular (LV) remodeling, but its effect in patients with ST-elevation myocardial infarction (STEMI) and a baseline occluded [thrombolysis in myocardial infarction (TIMI) flow grade B1] infarct-related artery (IRA) is unknown. According to the baseline TIMI flow grade, 110 patients with a first STEMI were divided into 2 groups. Group 1: 77 patients with TIMI flow B1 (40 patients treated with doxycycline and 37 with standard therapy, respectively), and a Group 2: 33 patients with TIMI flow 2-3 (15 patients treated with doxycycline and 18 with standard therapy, respectively). The two randomized groups were well matched in baseline characteristics. A 2D-Echo was performed at baseline and at 6 months, together with a coronary angiography, for the remodeling and IRA patency assessment, respectively. The LV end-diastolic volume index ( [1,3,4], and patient outcome [5,6]. Conversely, an occluded IRA (TIMI flow grade B1) before primary PCI, which is observed in almost 2/3 of patients with STEMI [2], is associated with increased LV remodeling despite an optimal epicardial mechanical recanalization (post-PCI TIMI flow grade 3) [4]. This ominous relationship between low baseline TIMI flow grade and LV remodeling has been attributed to different factors [7][8][9] including a greater ischemia/reperfusion injury [10].In patients with STEMI and LV dysfunction successfully treated with primary PCI, we recently demonstrated that a timely short-term therapy with doxycycline, the most potent metalloproteinases (MMPs) inhibitor of the tetracycline class of antibiotics, reduced both 6-month LV remodeling and infarct size [11]. Several pleiotropic properties of doxycycline related mainly to its ability to act as metalloproteinases (MMPs) inhibitor can explain these beneficial effects [12].